Purpose: To determine the efficacy and safety of a controlled-release formulation of doxazosin (gastrointestinal therapeutic system; DOX GITS) compared with placebo in patients with primary hypertension uncontrolled on their current antihypertensive.
P-395 OUTCOMES WITH PHYSICIAN'S CHOICE OF INITIAL DRUG IN CONVINCE
In hypertension trials comparing new and standard (S) regimens, the latter is often fixed by design for all patients. In the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial, the physician pre-selected the S treatment for each patient, either atenolol (A) or hydrochlorothiazide (H). Patients were then randomized to this pre-selected choice or verapamil (V). A propensity score for selection of H vs. A was calculated for each patient, based on the patient's age, systolic BP, and other baseline factors. We investigated whether patients in the S group would have lower event rates compared to V when assigned the treatment for which they had high propensity. Overall there were 729 patients with primary events (myocardial infarction, stroke or cardiovascular disease [CVD] death) and 1568 with secondary events (primary event or CVD hospitalization). The hazard ratio (HR: V/S) for each endpoint was calculated separately by quartile of propensity score and S selection. Higher propensity scores indicated a greater probability of selection to H. Results included:
In general, patients did better in the S group, compared to V, when assigned the initial treatment for which they had high propensity. For each endpoint the HR increased (positive slope) with increasing propen- Objective: To compare the mean dose of diltiazem ER (TIAZAC), added to current antihypertensive therapy, required to control blood pressure (BP) with dosage titration based on home electronic BP monitoring (hEBPM) or standard office sphygmomanometer (oSBPM).
Design and Methods: One-hundred-sixty-four patients (mean age, 62.5 years; 50% female) with DBP 90 -100 mmHg and SBP Ͻ190 mmHg or isolated systolic hypertension (SBP 140 -159 mmHg and DBP Ͻ 90 mmHg) were randomised to BP monitoring via hEBPM or oSBPM in a primary care setting. Patients were initially treated with diltiazem ER 180 or 240 mg, added to current antihypertensive therapy, titrated to 360 mg over 2 week intervals in patients not at a BP target of Ͻ140/90 mmHg. Patients were followed up for a maximum of 14 weeks, or 4 weeks if target BP was achieved.
Results: Of the 164 patients randomised, 141 completed the study. The mean baseline BP was 160.4/86.2 mmHg, and 157.2/88.4 mmHg, and mean starting dose of diltiazem ER was 207 mg and 200 mg, in the hEBPM and oSBPM groups, respectively. The proportion of patients reaching target BP were 81% and 87%, in the hEBPM and oSBPM groups, respectively, with the average dose required to reach target being 250 and 255 mg, respectively. Of the 141 evaluable patients, 14% and 35% were titrated to 300 and 360 mg, respectively.
Conclusion: Treatment of patients to BP target remains a significant clinical challenge. The TIARA study suggests that over 80% of patients can reach a BP target of Ͻ140/90 mmHg with appropriate titration of 
